Metabolic Dysregulation is at the Heart of Many Diseases and Maintaining Metabolic Function is Core to Health

Multifactorial diseases, where numerous pathologies and cellular networks are involved, require safe, multifunctional treatments. Additionally, maintaining metabolic function can be an important factor in maintaining health. Endogenous modulators, such as amino acids have the potential to elicit powerful, multifunctional effects through the cell and integrate the multiple cellular functions of metabolic modulators. Our current pipeline of AXA candidates are novel compositions of metabolic modulators that have the potential to harnesses this diverse activity, yield emergent synergies and reprogram dysregulated pathways target complex diseases and conditions with high unmet needs, or maintain health. Our robust pipeline includes endogenous modulator compositions specifically designed for our programs in liver, muscle and CNS.

  AXA candidates are novel compositions of metabolic modulators that harness the diverse activity of amino acid biology.

AXA candidates are novel compositions of metabolic modulators that harness the diverse activity of amino acid biology.

Amino acid biology impacts multiple cellular network systems:

  • Immune response and inflammation

  • Neurotransmitter signaling

  • Mitochondrial activation and TCA cycle

  • Protein synthesis

The potential benefits of AXA candidates include:

  • Multifunctionality - simultaneously targeting multiple networks of dysregulated pathways

  • Non-IND Clinical studies to understand the AXA Candidate safety, tolerability and impact on human biology* quickly provides an unprecedented breadth of information to inform development plan decisions

  • Designed and studied using our platform in a highly capital efficient manner

  • Opportunity to be used as stand-alone drug product, consumer health† product, or as a foundational combination agent in multi-drug therapeutic regimens

 

*Axcella conducts Non-IND, IRB-approved food studies to evaluate the safety and tolerability of its AXA candidates in human subjects, or effects on the normal structure or function of the body. Studies intended to directly support drug development will be conducted under an IND.